Table 2.
Patient characteristics and demographics (n = 92)
| Characteristics | n (%) or median (range) |
|---|---|
| Male | 55 (59.8) |
| Age at diagnosis (months) | 6.6 (0.5–210.4) |
| <6 months | 45 (48.9) |
| 6–11 months | 14 (15.2) |
| 12–23 months | 10 (10.9) |
| 24–59 months | 12 (13.0) |
| ≥60 months | 11 (12.0) |
| Presence of underlying disease† | 59 (64.1) |
| Diagnostic tool for RSV detection | |
| PCR | 77 (83.7) |
| Culture | 15 (16.3) |
| RSV subtype | |
| A | 49 (53.3) |
| B | 21 (22.8) |
| Unknown | 22 (23.9) |
| Co‐viral infection‡ | 16 (17.4) |
| PZ prophylaxis prior to RSV season (at least 1 dose) | 6 (6.5) |
| Status of RSV infection | |
| LRTI | 82 (89.1) |
| URTI | 10 (10.9) |
| Length of PICU stay (days) | 6 (1–154) |
| Ventilator support | |
| Requirement | 46 (50) |
| Duration (days) | 7.5 (1–139) |
| Tracheostomy | 3 (3.3) |
| Overall 30 day mortality | 7 (7.6)§ |
| RSV‐attributable 30 day mortality | 5 (5.4) |
†Prematurity, n = 7; chronic lung disease including bronchopulmonary dysplasia, interstitial lung disease and chronic aspiration, n = 11; congenital heart disease, n = 20; neuromuscular disorder due to mitochondrial disease and spinal muscular atrophy type 1, n = 2; airway malformation including tracheoesophageal fistula, lung sequestration, tracheomalacia and tracheal stenosis, n = 7; chromosomal anomaly including Down syndrome, n = 3; primary immunodeficiency, n = 1; acute kidney injury, n = 1; asthma, n = 1; arteriovenous malformation, n = 1; unknown severe developmental delay, n = 1; mediastinal lymphangiomatosis, n = 1; nephrotic syndrome, n = 1; renal tubular acidosis type 3, n = 1; and megacystic microcolon syndrome, n = 1. ‡Influenza A, n = 5; rhinovirus infection, n = 4; adenovirus infection, n = 4; coronavirus infection, n = 1; both parainfluenza and rhinovirus infection, n = 1; both adenovirus and rhinovirus infection, n = 1. §Two died from bacterial sepsis. LRTI, lower respiratory tract infection; PCR, polymerase chain reaction; PICU, pediatric intensive care unit; PZ, palivizumab; RSV, respiratory syncytial virus; URTI, upper respiratory tract infection.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.